Lonza Group AG
Aperta
SettoreSettore sanitario
494.7 1.17
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
489
Massimo
500.4
Entrata | 57M 483M |
|---|---|
Vendite | -621M 3B |
P/E Media del settore | 37.325 49.052 |
Rendimento da dividendi | 1.02 |
Margine di Profitto | 16.345 |
Dipendenti | 20,000 |
EBITDA | -181M 822M |
Raccomandazioni | Fortemente da comprare |
|---|---|
Previsioni per 12 mesi | +35.43% upside |
Rendimento da dividendi Media del settore | 1.02% 2.36% |
|---|---|
Utili prossimi | 22 lug 2026 |
Capitalizzazione di Mercato | -4.8B 34B |
|---|---|
Apertura precedente | 493.53 |
Chiusura precedente | 494.7 |
Notizie sul Sentiment di mercato
By Acuity
100%
0%
330 / 342 Classifica in Healthcare
Lonza Group AG Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Chi Siamo Lonza Group AG
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.